On September 26, 2024, Lawrence Kenyon, Chief Financial Officer of Outlook Therapeutics Inc (OTLK, Financial), purchased 5,000 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 5,946 shares of Outlook Therapeutics Inc.
Outlook Therapeutics Inc is engaged in the development of ophthalmic formulations. The company focuses on developing and commercializing complex monoclonal antibodies for various ophthalmic indications.
The shares were acquired at a price of $5.69 per share, valuing the transaction at approximately $28,450. This acquisition has increased the insider's stake in the company significantly.
Over the past year, the insider has purchased a total of 5,000 shares and has not sold any shares. The insider transaction history for Outlook Therapeutics Inc shows a trend of more insider buying than selling. In the past year, there have been three insider buys and zero insider sells.
The stock currently has a market cap of approximately $126.32 million. The recent trading price also reflects various valuation metrics such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This insider purchase could be a signal to investors about the insider's confidence in the future prospects of Outlook Therapeutics Inc.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
